Oxaliplatin is one of the three FDA-approved platinum anticancer drugs and considered a third generation drug, discovered after the first generation drug cisplatin and second generation drug carboplatin. It is known to react with proteins and DNA nucleotides in the body. Reaction with DNA occurs primarily at guanosine residues and secondarily at adenine residues for oxaliplatin and other platinum drugs. We have previously studied oxaliplatin and an analog with additional steric hindrance in the amine ligand and found that the analog had different reactivity with methionine. Now, we have prepared oxaliplatin and its three analogs Pt(Me2dach)(ox), Pt(en)(ox) and Pt(Me4en)(ox) and have reacted each platinum compound with both guanine and adenine nucleotides at pH 4 and pH 7 at different molar ratios. These reactions have been characterized by Nuclear Magnetic Resonance (NMR) spectroscopy equipment over time to observe the formation of products and compare them on the basis of their kinetics and binding affinities. NMR has shown that even under the conditions of excess platinum, the dominant products are usually those with two nucleotides coordinated to one platinum center. Reactions are faster at pH 7 than pH 4 due to deprotonation of phosphate group. Reactions of GMP with a platinum center are faster than reaction with AMP because of the chelate formed by the oxalate ligand. The extra methyl groups on the oxaliplatin analogs do not appear to slow down the reactions with nucleotides considerably. The pH generally affects the rate but does not substantially affect the product distribution.